# US 2026/0062464 A1 · Monoclonal antibodies that bind to the underside of influenza viral neuraminidase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062464 A1
- Document ID: US20260062464A1
- Status: Published application
- Kind: A1
- Application number: 19/100,498
- Filed: 2023-07-28
- Published: 2026-03-05
- Earliest claimed: 2022-08-01
- Assignees: The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Inventors: Masaru Kanekiyo; Julia Lederhofer; Yaroslav Tsybovsky; Sarah F. Andrews
- Web page: https://patentgrep.com/patent/US20260062464A1

## CPC

- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- A61P 31/16: for influenza or rhinoviruses
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Monoclonal antibodies are antigen binding fragments are disclosed that specifically bind to the underside of influenza A neuraminidase (NA). In some aspects, these antibodies and antigen binding fragments are used for in methods of treating a subject with an influenza A infection, such as an H3N2 infection. In more aspects, these antibodies and antigen binding fragments and bispecific antibodies for detection of an influenza virus in a sample, and for selecting vaccines.

## Claims

### Claim 1

An isolated monoclonal antibody or antigen binding fragment thereof, comprising:
a heavy chain variable region (VH) and a light chain variable region (VL) comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 and a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3, wherein the VH and VL are set forth as one of:
a) SEQ ID NOs: 1 and 5, respectively (NDS.1);
b) SEQ ID NOs: 17 and 21, respectively (NDS.3);
c) SEQ ID NOs: 9 and 13, respectively (NDS.1.1);
d) SEQ ID NOs: 25 and 29, respectively (NDS.1.2);
e) SEQ ID NOs: 33 and 37, respectively (NDS.6);
f) SEQ ID NOs: 41 and 45, respectively (NDS.8);
g) SEQ ID NOs: 49 and 53, respectively (NDS.5); or
h) SEQ ID NOs: 57 and 61, respectively (NDS.7);
wherein the monoclonal antibody specifically binds to influenza A neuraminidase (NA) protein and inhibits an N2 influenza A virus.

### Claim 2 (depends on 1)

The isolated monoclonal antibody or antigen binding fragment of claim 1, wherein:
a) the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 comprise the amino acids sequences set forth as SEQ ID NOs: 2, 3, 4, 6, 7, and 8, respectively;
b) the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 comprise the amino acids sequences set forth as SEQ ID NOs: 18, 19, 20, 22, 23, and 24 respectively;
c) the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 comprise the amino acids sequences set forth as SEQ ID NOs: 10, 11, 12, 14, 15, and 16, respectively;
d) the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 comprise the amino acids sequences set forth as SEQ ID NOs: 26, 27, 28, 30, 31, and 32 respectively;
e) the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 comprise the amino acids sequences set forth as SEQ ID NOs: 34, 35, 36, 38, 39, and 40 respectively;
f) the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 comprise the amino acids sequences set forth as SEQ ID NOs: 42, 43, 44, 46, 47, and 48, respectively;
g) the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 comprise the amino acids sequences set forth as SEQ ID NOs: 50, 51, 52, 54, 55, and 56, respectively; or
h) the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 comprise the amino acids sequences set forth as SEQ ID NOs: 58, 59, 60, 62, 63, and 64, respectively.

### Claim 3 (depends on 1)

The isolated monoclonal antibody or antigen binding fragment of claim 1, wherein
a) the VH and the VL comprise the amino acid sequences at least 90% identical to the amino acid sequences set forth as SEQ ID NOs: 1 and 5, respectively;
b) the VH and the VL comprise the amino acid sequences at least 90% identical to the amino acid sequences set forth as SEQ ID NOs: 17 and 21, respectively;
c) the VH and the VL comprise the amino acid sequences at least 90% identical to the amino acid sequences set forth as SEQ ID NOs: 9 and 13, respectively;
d) the VH and the VL comprise the amino acid sequences at least 90% identical to the amino acid sequences set forth as SEQ ID NOs: 25 and 29, respectively;
e) the VH and the VL comprise the amino acid sequences at least 90% identical to the amino acid sequences set forth as SEQ ID NOs: 33 and 37, respectively;
f) the VH and the VL comprise the amino acid sequences at least 90% identical to the amino acid sequences set forth as SEQ ID NOs: 41 and 45, respectively;
g) the VH and the VL comprise the amino acid sequences at least 90% identical to the amino acid sequences set forth as SEQ ID NOs: 49 and 53, respectively; or
h) the VH and the VL comprise the amino acid sequences at least 90% identical to the amino acid sequences set forth as SEQ ID NOs: 57 and 61, respectively.

### Claim 4 (depends on 1)

The isolated monoclonal antibody or antigen binding fragment of claim 1, comprising a human framework region.

### Claim 5 (depends on 1)

The isolated monoclonal antibody or antigen binding fragment of claim 1, wherein:
a) the VH and the VL comprise the amino acid sequences set forth as SEQ ID NOs: 1 and 5, respectively;
b) the VH and the VL comprise the amino acid sequences set forth as SEQ ID NOs: 17 and 21, respectively;
c) the VH and the VL comprise the amino acid sequences set forth as SEQ ID NOs: 9 and 13, respectively;
d) the VH and the VL comprise the amino acid sequences set forth as SEQ ID NOs: 25 and 29, respectively;
e) the VH and the VL comprise the amino acid sequences set forth as SEQ ID NOs: 33 and 37, respectively;
f) the VH and the VL comprise the amino acid sequences set forth as SEQ ID NOs: 41 and 45, respectively;
g) the VH and the VL comprise the amino acid set forth as SEQ ID NOs: 49 and 53, respectively; or
h) the VH and the VL comprise the amino acid sequences set forth as SEQ ID NOs: 57 and 61, respectively.

### Claim 6 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein the antibody comprises a human constant domain.

### Claim 7 (depends on 1)

The isolated monoclonal antibody or antigen binding fragment of claim 1, wherein the antibody is a human antibody.

### Claim 8 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein the antibody is an IgG.

### Claim 9 (depends on 1)

The isolated monoclonal antibody of claim 1, comprising a recombinant constant domain comprising a modification that increases the half-life of the antibody.

### Claim 10 (depends on 9)

The isolated monoclonal antibody of claim 9, wherein the modification increases binding to the neonatal Fc receptor.

### Claim 11 (depends on 1)

The antigen binding fragment of claim 1.

### Claim 12 (depends on 11)

The antigen binding fragment of claim 11, wherein the antigen binding fragment is a Fv, Fab, F(ab′)2, scFV or a scFV2 fragment.

### Claim 13 (depends on 1)

The isolated monoclonal antibody or antigen binding fragment of claim 1, wherein the influenza virus is an H3N2 influenza virus.

### Claim 14 (depends on 1)

The isolated monoclonal antibody or antigen binding fragment of any one of claim 1, conjugated to a detectable marker.

### Claim 15 (depends on 1)

A bispecific antibody comprising the monoclonal antibody or antigen binding fragment of claim 1.

### Claim 16 (depends on 1)

An isolated nucleic acid molecule encoding the monoclonal antibody or antigen binding fragment of claim 1, or a bispecific antibody comprising the antibody or antigen binding fragment.

### Claim 17 (depends on 16)

The nucleic acid molecule of claim 16, wherein the nucleic acid molecule is a cDNA sequence encoding the VH or VL.

### Claim 18 (depends on 17)

The nucleic acid molecule of claim 17, wherein the nucleic acid molecule is a cDNA sequence encoding the VH and/or VL of an scFv antigen binding fragment.

### Claim 19 (depends on 16)

The nucleic acid molecule of claim 16, operably linked to a promoter.

### Claim 20 (depends on 16)

A vector comprising the nucleic acid molecule of any claim 16.

### Claim 21 (depends on 16)

A host cell comprising the nucleic acid molecule of claim 16 or vector comprising the nucleic acid molecule.

### Claim 22 (depends on 1)

A pharmaceutical composition comprising an effective amount of the antibody or antigen binding fragment of claim 1, a bispecific antibody comprising the antibody or antigen binding fragment, a nucleic acid molecule encoding the antibody, antigen binding fragment or bispecific antibody, or a vector comprising the nucleic acid molecule; and
a pharmaceutically acceptable carrier.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A method of producing an antibody or antigen binding fragment that specifically binds to an influenza virus, comprising:
expressing one or more nucleic acid molecules encoding the antibody or antigen binding fragment of claim 1, or a bispecific antibody comprising the antibody or antigen binding fragment in a host cell; and
purifying the antibody, antigen binding fragment, or bispecific antibody from the host cell.

### Claim at position 25

25-26. (canceled)

### Claim 27 (depends on 1)

A method of inhibiting an influenza virus infection in a subject, comprising administering an effective amount of the antibody or antigen binding fragment of claim 1, a nucleic acid molecule encoding the antibody or antigen binding fragment, a vector comprising the nucleic acid molecule, or pharmaceutical composition comprising the antibody, antigen binding fragment, nucleic acid molecule or vector 23 to the subject, wherein the subject has or is at risk of the influenza virus infection

### Claim 28

(canceled)

### Claim 29 (depends on 1)

A method of identifying a protein as a vaccine comprising:
contacting the protein with the monoclonal antibody or antigen binding fragment of claim 1 under conditions sufficient to form an immune complex; and
detecting the presence of an immune complex,
wherein the presence of the immune complex indicates that the protein is a vaccine for an influenza virus infection.

### Claim at position 29

30-34. (canceled)
